Tenofovir disoproxil fumarate: In chronic hepatitis B

Drugs

Volumn 69, Issue 16, 2009, Pages 2245-2256

  Perry, Caroline M ^a   Simpson, Dene ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ACUTE KIDNEY FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BACKACHE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FANCONI RENOTUBULAR SYNDROME; FATIGUE; GENE MUTATION; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FAILURE; KIDNEY TUBULE DISORDER; NAUSEA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTOPENIA; TOXIC MYOPATHY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN;

ADENINE; ADMINISTRATION, ORAL; ADULT; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70350518852     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10482940-000000000-00000     Document Type: Review

References (36)

1. Lok ASF, McMahon BJ. AALSD practice guidelines. Chronic hepatitis B: update 2009 [online]. Available from URL: http:// www.aasld.org/ practiceguidelines/Documents/Bookmarked% 20Practice%20Guidelines/Chronic-Hep-B- Update-2009 [Accessed 2009 Sep 30]
2. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, et al. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178
3. Liaw Y-F, Leung N, Kao J-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-242
5. Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: Mono or combination therapy? J Hepatol 2008 Mar; 48 (3): 383-386
6. Hoofnagle JH, Doo E, Liang TJ, et al. Management of he-patitis B: summary of a clinical research workshop. Hepa-tology 2007 Apr; 45 (4): 1056-1075
7. National Institute for Health and Clinical Excellence. He-patitis B: entecavir [online]. Available from URL: http:// www.nice.org.uk/TA153 [Accessed 2009 Sep 30]
8. European Medicines Agency. Summary of product characteristics. Viread (tenofovir disoproxil fumarate) [online]. Available from URL: http://www.emea.europa.eu/humandocs/ Humans/EPAR/viread/viread.htm [Accessed 2009 Sep 14]
9. Gilead Sciences Inc. Viread® (tenofovir disoproxil fumarate) US prescribing information [online]. Available from URL: http://www.gilead.com/pdf/ viread-pi.pdf [Accessed 2009 Sep 14]
10. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Teno-fovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005; 65 (3): 413-432
11. Chapman TM, McGavin JK, Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63 (15): 1597-1608
12. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003 Oct; 16 (4): 569-596 (Pubitemid 37296550)
13. Delaney 4th WE, Ray AS, Yang H, et al. Intracellular meta-bolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006 Jul 50 7 2471-2477
14. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxocity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001 Apr-Jul; 20 (4-7): 641-648
15. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008 Dec 4; 359 (23): 2442-2455
16. Snow-Lampart A, Chappell B, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300mg QD [poster no. 977]. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31-Nov 4; San Francisco (CA)
17. Qi X, Xiong S, Yang H, et al. In vitro susceptibility of ade-fovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12 (3): 355-362
18. Tan J, Degertekin B, Wong SN, et al. Tenofovir mono-therapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008 Mar; 48 (3): 391-398
19. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10 (5): 625-633
20. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10 (6): 727-734
21. Fung S, Mazzulli T, Sherman M. Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B [poster no. 880]. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31-Nov 4; San Francisco (CA)
22. Lada O, Benhamou Y, Cahour A, et al. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 2004 Jun; 9 (3): 353-363
23. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004 Dec; 40 (6): 1421-1425
24. van Bommel F, Mauss S, Schurmann D, et al. No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years. Hepatology 2006 Oct 1; 44 (4 Suppl. 1): 549A
25. van Bommel F, Mauss S, Zollner B, et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir [abstract no. 184 plus poster]. Hepatology 2005 Oct; 42 (4 Suppl. 1): 269A
26. Audsley J, Arrafin N, Yuen L, et al. Surveillance of hepatitis B virus mutations during tenofovir treatment in HIV/HBV-co-infected individuals [abstract no. 942]. 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA)
27. Zhou X, Pietropaolo K, Becker M, et al. Absence of phar-macokinetic drug-drug interaction between telbivudine and tenofovir [abstract no. S1782]. Digestive Disease Week; 2009 May 19-24; Washington, DC
28. Wang C, Buti M, Hadziyannis S, et al. Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis [abstract no. M1910]. Gastroenterology 2008 April; 134 (4 Suppl. 1): A808-9
29. Younossi ZM, Benhamou Y, Gane EJ, et al. Lack of influ-ence of baseline genotype on antiviral response in subjects with chronic hepatitis B infection receiving tenofovir DF 300mg qd for 1 year [abstract no. M1913]. Gastro-enterology 2008 Apr; 134 (4 Suppl. 1): A809
30. Peters MG, Andersen J, Lynch P, et al. Randomized con-trolled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006 Nov; 44 (5): 1110-1116
31. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of teno-fovir disoproxil fumarate in antiretroviral therapy-naive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004 Apr 1; 189 (7): 1185-1192
32. Lee S, Heathcote E, Sievert W, et al. Tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B participating in Studies 102 and 103 [abstract no. 980]. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008 Oct 31-Nov 4; San Francisco (CA)
33. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003 Jan 3; 17 (1): F7-10
34. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007 Jun 19; 21 (10): 1273-1281
35. Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42 (2): 283-290
36. Wong SN, Lok AS. Tenofovir disoproxil fumarate: role in hepatitis B treatment. Hepatology 2006 Aug; 44 (2): 309-13